Your Score No Longer Decides. Your Critique Does.
For decades, the unwritten rule of NIH grant writing was this: write to the score. Your Significance, Approach, and Innovation needed to score well. Reviewers assigned numbers, the numbers rolled up to an impact score, and if that impact score was inside your institute's payline, you were funded.
As of the January 2026 Council round, that rule is gone.
The NIH Unified Funding Strategy, effective during that round of Advisory Council meetings, replaced paylines with a standard set of core tenets that every Institute, Center, and Office now uses to make funding decisions: scientific merit assessed during peer review, alignment with the NIH mission, program balance, career stage, geographic balance, and stewardship of available funds.
Notice what happened to peer review in that list.
It is still there. It is the first item. It is not the only item.
Most of the commentary on this change has focused on what applicants lose. Virginia Tech's research office wrote that investigators will no longer be able to predict funding likelihood solely from their summary statement. Science called the absence of a payline a source of enormous uncertainty and anxiety for applicants. Those observations are correct. They are also incomplete.
Because the more important story is what has happened to the document your reviewers produce.
What reviewers do, and what they do not do
Let me be careful here, because the NIH process is easy to describe loosely and get wrong.
Reviewers score scientific and technical merit. They do not decide who gets funded. They do not discuss paylines, funding likelihood, or budget decisions. What they produce — in addition to their scores — is a written critique that captures the scientific and technical merits and weaknesses of the application. That critique travels with the score from the study section to program staff to the Advisory Council to the Institute or Center director.
Under paylines, the critique was mostly documentation. It explained how reviewers arrived at the score, and it gave applicants material for revision if their application was not funded. The score was the primary currency of funding because the payline mechanically converted scores into funding decisions.
Under the Unified Funding Strategy, that mechanical conversion no longer exists.
When an Institute or Center director makes a funding decision now, they are not reading the score in isolation. They are reading the critique alongside it, as one of several inputs into a decision that also considers programmatic priorities, career stage, geographic distribution, and portfolio balance. The critique is what gives that decision-making conversation texture. The score gives it a number. The number is no longer enough.
This is the shift most applicants have not absorbed yet.
What this changes about writing
Under paylines, your writing task was straightforward. Produce a proposal that earns a strong score from reviewers. The writing moves that accomplished that were well understood: lead with significance, specify the aims cleanly, demonstrate rigor, address feasibility, show innovation. Do all of that and the score came out in the right range. The rest was procedural.
Under the Unified Funding Strategy, the writing task has an additional layer.
You still need your reviewers to score you well. That has not changed. What has changed is that you also need them to produce a critique rich enough to survive the downstream funding decision conversation. A strong score with a tepid critique no longer carries the application the way it used to, because program staff and directors now have latitude to weigh the critique alongside other factors. A strong score paired with a critique that says, in effect, this is important, here is why, and here is what will happen if we fund it — that pairing is what moves an application from the reviewed pile into the funded pile.
Which means the thing you have always needed — a reviewer who can articulate the value of your work to people who were not in the review room — is no longer optional or merely helpful. It is now the mechanism by which applications get funded.
The critique is written by the reviewer. You decide what is in it.
Here is the move most grant writers miss.
A reviewer's critique is not a transcription of your application. It is a reconstruction. The reviewer reads your 140-page document at 11 PM on a Tuesday, forms an overall impression, and then writes three or four paragraphs that capture — in their own language — what the application is about, what is strong about it, and what is weak about it.
If your application gave them clear, specific language to describe why your work matters, that language shows up in the critique. If your application gave them vague, decorative language about importance, the critique reflects that vagueness.
You are not writing the critique. The reviewer is. But the raw material of the critique is whatever you put on the page.
This is the fifth translation gap in the Lost in Translation framework — between your vision and their advocacy. Under paylines, this gap was important but subordinate to the scoring mechanics. Under the UFS, it has become the central translation task of the application. Everything else in your proposal exists, in part, to equip the critique with the sentences the reviewer will need.
One test to run before you submit
Take your Impact paragraph. Read the two or three sentences that describe why this work matters.
Now imagine a program officer who read your application once, two months ago, sitting in a funding decision conversation. That program officer needs to describe your work in twenty or thirty seconds, in language borrowed from what was said about your proposal in the study section. Can the sentences in your Impact paragraph survive that trip? Could they be paraphrased, adopted, repeated?
If the sentences are generic — if they could belong to ten thousand other grants — they cannot be carried. They will be replaced, in the program officer's summary, by whatever the reviewer's critique happens to have said. Which may or may not be what you meant.
If the sentences are specific — if they identify the actual change your work would produce, in language a non-specialist can repeat — they travel. They become the scaffolding of the funding decision conversation.
This is the test I would apply to any paragraph in your application that is doing strategic work. Not just Impact. Significance. The opening of your Specific Aims. The framing sentences of your Approach. Each one should pass the same test: could this be lifted and carried into a conversation I am not present for?
If yes, you have written a proposal for the post-payline world.
If no, you have written a proposal for the world that ended in January.
What early-career investigators gain
There is a quiet upside in this change that most commentary has missed.
Under paylines, early-career investigators competed primarily on scores. A 15th-percentile R01 from a first-time investigator was evaluated the same way as a 15th-percentile R01 from a three-time-funded PI. Institutional reputation and investigator track record shaped the score before it was ever written down — sometimes subtly, sometimes not.
Under the UFS, career stage is now an explicit funding consideration, not a hidden one. For an early-career investigator whose application lands at a score that would have been just outside an old payline, the new process creates a legitimate pathway to funding that the old process foreclosed.
But that pathway only opens if your critique reads like the work of a confident, capable scientist whose career is worth investing in. Applications that apologize for newness, hedge on ambition, or over-explain limitations produce critiques that echo those doubts. A reviewer can only advocate for an application with the language the application gave them. If the application wrote itself in the register of apology, the critique will not invent confidence the applicant did not claim.
The system is saying: we want to invest in early-career investigators. If your writing says I am not sure I am ready to be invested in, the system will take you at your word.
The translation gap has moved
The fifth translation gap — between your vision and the reviewer's advocacy — was always the hardest to teach because it was the most abstract. Most applicants could not really picture the downstream conversation their application would need to survive. They wrote for the reviewer's eyes on the page, not for what the reviewer would later have to say about the work.
The Unified Funding Strategy has made that gap concrete. The downstream conversation is no longer imaginary. It is the funding decision conversation at your target Institute, informed by the critique your reviewer will write, shaped by the language your application did or did not give that reviewer to work with.
If you are preparing an application for a Cycle III 2026 submission, this is the frame to write from. Your score gets you discussed. Your critique gets you funded. The critique is written by someone else — but the sentences they will reach for are the sentences you put on the page.
Write them with that conversation in mind.
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM is a behavioral scientist, NIH-funded investigator, and creator of the Lost in Translation grantsmanship curriculum. She is teaching a free webinar on May 8: "Why Good Science Gets Lost." Register at www.lisacarterbawa.com/may8.
Sources
NIH. "Implementing a Unified NIH Funding Strategy to Guide Consistent and Clearer Award Decisions." November 21, 2025. https://grants.nih.gov/news-events/nih-extramural-nexus-news/2025/11/implementing-a-unified-nih-funding-strategy-to-guide-consistent-and-clearer-award-decisions
NIH. "Institute and Center Director Perspectives on Implementing the NIH Unified Funding Strategy." February 23, 2026. https://grants.nih.gov/news-events/nih-extramural-nexus-news/2026/02/nih-institute-and-center-director-perspectives-on-implementing-the-nih-unified-funding-strategy
Kaiser, J. "NIH shake-up to grant decision-making sparks concern over political meddling." Science, November 24, 2025.
